RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000002.xml
Aktuelle Dermatologie 2011; 37(1/02): 47-56
DOI: 10.1055/s-0030-1256016
DOI: 10.1055/s-0030-1256016
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York
Primär kutane B-Zell-Lymphome
Primary Cutaneous B-Cell LymphomasWeitere Informationen
Publikationsverlauf
Publikationsdatum:
03. Februar 2011 (online)

Lernziele
Kenntnisse über primär kutane B-Zell-Lymphome:
Terminologie und Klassifikation Klinik, Histologie und Diagnosestellung Stadieneinteilung Therapie und Prognose
Literatur
- 1 Willemze R, Jaffe E S, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105 3768-3785
- 2 Assaf C, Gellrich S, Steinhoff M et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges. 2007; 5 662-668
- 3 Dummer R, Stadler R, Sterry W. Cutaneous lymphomas. J Dtsch Dermatol Ges. 2007; 5 605-617
- 4 Senff N J, Noordijk E M, Kim Y H European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma et al.. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008; 112 1600-1609
- 5 Burg G, Kempf W, Cozzio A et al. Cutaneous malignant lymphomas: update 2006. J Dtsch Dermatol Ges. 2006; 4 914-933
- 6 Fink-Puches R, Zenahlik P, Bäck B et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. 2002; 99 800-805
- 7 Child F J, Woollons A, Price M L et al. Multiple cutaneous immunocytoma with secondary anetoderma: a report of two cases. Br J Dermatol. 2000; 143 165-170
- 8 de Leval L, Harris N L, Longtine J et al. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol. 2001; 25 732-741
- 9 Swerdlow S H, Campo E, Harris N L et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues.. Lyon: IARC Press; 2008
- 10 Grange F, Petrella T, Beylot-Barry M et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood. 2004; 103 3662-3668
- 11 Hallermann C, Niermann C, Fischer R J et al. New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas. J Am Acad Dermatol. 2007; 56 588-597
- 12 Ponzoni M, Ferreri A J, Campo E et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol. 2007; 25 3168-3173
- 13 Koens L, Vermeer M H, Willemze R et al. IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma. Am J Surg Pathol. 2010; 34 1043-1048
- 14 Kim Y H, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110 479-484
- 15 Cronin C G, Swords R, Truong M T et al. Clinical utility of PET/CT in lymphoma. Am J Roentgenol. 2010; 194 W91-W103
- 16 Senff N J, Willemze R. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2007; 157 1205-1211
- 17 Stadler R, Assaf C, Klemke C D et al. Short German guidelines: cutaneous lymphomas. J Dtsch Dermatol Ges. 2008; 6 (Suppl. 1) S25-S31
- 18 Cerroni L, Zöchling N, Pütz B et al. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997; 24 457-461
- 19 Goodlad J R, Davidson M M, Hollowood K et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol. 2000; 24 1279-1285
- 20 Li C, Inagaki H, Kuo T T et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases. Am J Surg Pathol. 2003; 27 1061-1069
- 21 Wood G S, Kamath N V, Guitart J et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol. 2001; 28 502-507
- 22 Senff N J, Hoefnagel J J, Jansen P M et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007; 25 1581-1587
- 23 Kodama K, Massone C, Chott A et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood. 2005; 106 2491-2497
- 24 Fink-Puches R, Wolf I H, Zalaudek I et al. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005; 52 847-853
- 25 Mian M, Marcheselli L, Luminari S et al. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). Ann Hematol. [in press]
- 26 Pulini S, Rupoli S, Goteri G et al. Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies. Eur J Haematol. 2009; 82 184-193
- 27 Mounier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003; 101 4279-4284
- 28 Skvortsova I, Skvortsov S, Popper B A et al. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin’s lymphoma cells via caspase-dependent and – independent mechanisms. J Radiat Res. (Tokyo) 2006; 47 183-196
- 29 Skvortsova I, Popper B A, Skvortsov S et al. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin’s lymphoma cells. J Radiat Res. (Tokyo) 2005; 46 241-248
Dr. med. Oliver Inhoff
Funktionsoberarzt
Hautklinik/Hauttumorzentrum
Rheinpfalz
Klinikum Ludwigshafen
Bremserstr. 79
67063 Ludwigshafen
eMail: inhoffo@klilu.de